Skip to content

Loxo Oncology, Inc.

Delisted

CIK 1581720fmd_0RY2XBH01XETP3E268B67ZH8QDManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jul 01, 2013 to Sep 30, 2018, 20 periods

Latest annual · FY2017

Millions
Total revenues
0
Operating income
(152)
Net income
(149)
Free cash flow
107

Latest quarter · Q3 FY2018

Millions
Total revenues
42
Operating income
(30)
Net income
(27)
Free cash flow
(63)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2014 to FY2017
n/m

Loxo Oncology, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2017FY2016ChangeSource
Revenue$010-K 2018-03-01 · proof
Operating income-$152.4 million-$73.2 million10-K 2018-03-01 · proof
Net income-$148.9 million-$72.4 million10-K 2018-03-01 · proof
Cash from operating activities$107.8 million-$51.3 million10-K 2018-03-01 · proof
Free cash flow$107 million-$51.6 million10-K 2018-03-01 · proof
Total assets$783.4 million$145.3 million+439.1%10-K 2018-03-01 · proof
Total liabilities$405.2 million$15.1 million+2,575.9%10-K 2018-03-01 · proof
Cash and cash equivalents$142 million$30.4 million+367.6%10-K 2018-03-01 · proof
What was Loxo Oncology, Inc.'s revenue in fiscal 2017?
Loxo Oncology, Inc. reported revenue of $0 for fiscal 2017 (the year ended Dec 31, 2017). Source: the 10-K filed with the SEC on Mar 1, 2018. SEC
What was Loxo Oncology, Inc.'s operating income in fiscal 2017?
Loxo Oncology, Inc. reported operating income of -$152.4 million for fiscal 2017 (the year ended Dec 31, 2017), against -$73.2 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2018. SEC
What was Loxo Oncology, Inc.'s net income in fiscal 2017?
Loxo Oncology, Inc. reported net income of -$148.9 million for fiscal 2017 (the year ended Dec 31, 2017), against -$72.4 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2018. SEC
What was Loxo Oncology, Inc.'s cash from operating activities in fiscal 2017?
Loxo Oncology, Inc. reported cash from operating activities of $107.8 million for fiscal 2017 (the year ended Dec 31, 2017), against -$51.3 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2018. SEC
What was Loxo Oncology, Inc.'s free cash flow in fiscal 2017?
Loxo Oncology, Inc. reported free cash flow of $107 million for fiscal 2017 (the year ended Dec 31, 2017), against -$51.6 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2018. SEC
What are Loxo Oncology, Inc.'s total assets?
As of Dec 31, 2017, Loxo Oncology, Inc. reported total assets of $783.4 million, against $145.3 million a year earlier (+439.1%). Source: the 10-K filed with the SEC on Mar 1, 2018. SEC
What are Loxo Oncology, Inc.'s total liabilities?
As of Dec 31, 2017, Loxo Oncology, Inc. reported total liabilities of $405.2 million, against $15.1 million a year earlier (+2,575.9%). Source: the 10-K filed with the SEC on Mar 1, 2018. SEC
What are Loxo Oncology, Inc.'s cash and cash equivalents?
As of Dec 31, 2017, Loxo Oncology, Inc. reported cash and cash equivalents of $142 million, against $30.4 million a year earlier (+367.6%). Source: the 10-K filed with the SEC on Mar 1, 2018. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1581720&period_type=annual&limit=5"

Information only, not investment advice.